FDA Looks To Capitol Hill For New Authority For Globalization Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency still plans to move forward with coalition-building and increased data-sharing aspects of globalization initiative.
You may also be interested in...
U.S. FDA Wary About “Paying The Price” For Mistakes Based On Foreign Data
It is going to take time for the public and policymakers to get comfortable with the idea of U.S. FDA making regulatory decisions based on information from other countries, Commissioner Hamburg says.
FDA Wary About “Paying The Price” For Mistakes Based On Foreign Data
It is going to take time for the public and policymakers to get comfortable with the idea of FDA making regulatory decisions based on information from other countries, Commissioner Hamburg says.
FDA Grades Itself Highly In Reports On Safety Of Imported Products And Marketed Drugs
As Congressional markups of user fee bills looms, the agency describes actions it has taken to protect the international supply chain in its Global Engagement report; another report notes the REMS and drug safety studies it has mandated under its postmarket drug safety program.